on November 2, 2013
Last week, word leaked that GW Pharmaceuticals will supply the US government with cannabis-derived cannabidiol (C-B-D) for a special Investigative New Drug program, so at least 50 children with epilepsy can try the non-psychoactive marijuana-derived compound as a way to control seizures and treat their disease.
Now, a GW-funded study published in the journal Anticancer Research has shown that cannabinoids – “the bioactive components of the cannabis plant that display a diverse range of therapeutic qualities” -- can kill cancerous cells related to leukemia.
"Cannabinoids have a complex action; it hits a number of important processes that cancers need to survive," Dr. Wai Liu, an author of the study, told The Huffington Post. "For that reason, it has really good potential over other drugs that only have one function. I am impressed by its activity profile, and feel it has a great future, especially if used with standard chemo therapies."
One thing that doesn't impress the St. George's University of London oncologist, and his funders at GW Pharmaceuticals, however, is cannabis itself. While cannabinoids derived from marijuana display a "diverse range of therapeutic qualities" that "target and switch off" cancer cell growth, Dr. Liu described traditional cannabis oil as “crude,” taking great pains to tout pharmaceutical preparations over all other methods of ingesting this medicine. A position that neatly aligns with GW Pharmaceutical's vested interest in eliminating any and all competition for its patented, “whole-plant extracts” of cannabis.
You could read the whole story here: https://www.facebook.com/Canadian420nurses .
Now, a GW-funded study published in the journal Anticancer Research has shown that cannabinoids – “the bioactive components of the cannabis plant that display a diverse range of therapeutic qualities” -- can kill cancerous cells related to leukemia.
"Cannabinoids have a complex action; it hits a number of important processes that cancers need to survive," Dr. Wai Liu, an author of the study, told The Huffington Post. "For that reason, it has really good potential over other drugs that only have one function. I am impressed by its activity profile, and feel it has a great future, especially if used with standard chemo therapies."
One thing that doesn't impress the St. George's University of London oncologist, and his funders at GW Pharmaceuticals, however, is cannabis itself. While cannabinoids derived from marijuana display a "diverse range of therapeutic qualities" that "target and switch off" cancer cell growth, Dr. Liu described traditional cannabis oil as “crude,” taking great pains to tout pharmaceutical preparations over all other methods of ingesting this medicine. A position that neatly aligns with GW Pharmaceutical's vested interest in eliminating any and all competition for its patented, “whole-plant extracts” of cannabis.
You could read the whole story here: https://www.facebook.com/Canadian420nurses .
1 Liked
1 person likes this.
Sponsored
